Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 2 458.5 JPY -0.79% Market Closed
Market Cap: 2.9T JPY
Have any thoughts about
Olympus Corp?
Write Note

Net Margin
Olympus Corp

1.7%
Current
18%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
1.7%
=
Net Income
16.6B
/
Revenue
963.3B

Net Margin Across Competitors

Country JP
Market Cap 2.9T JPY
Net Margin
2%
Country US
Market Cap 204.9B USD
Net Margin
14%
Country US
Market Cap 195.2B USD
Net Margin
29%
Country US
Market Cap 146.7B USD
Net Margin
16%
Country US
Market Cap 132.6B USD
Net Margin
11%
Country IE
Market Cap 110.6B USD
Net Margin
12%
Country US
Market Cap 64.7B USD
Net Margin
9%
Country DE
Market Cap 55.6B EUR
Net Margin
8%
Country CN
Market Cap 319.2B CNY
Net Margin
34%
Country US
Market Cap 41.6B USD
Net Margin
74%
Country US
Market Cap 37.7B USD
Net Margin
9%
No Stocks Found

Olympus Corp
Glance View

Market Cap
2.9T JPY
Industry
Health Care

Olympus Corp., a global leader in optical and digital precision technology, has carved a remarkable niche in the healthcare and life sciences sectors. Founded in Japan in 1919, the company initially focused on cameras and microscopes but has since evolved into a dominant player in the medical device arena, particularly known for its innovative imaging systems, endoscopy equipment, and surgical solutions. Olympus's commitment to enhancing healthcare outcomes is underscored by its significant investments in research and development, enabling the company to deliver cutting-edge solutions that improve patient care and empower healthcare professionals. With a strong presence in over 40 countries, Olympus not only addresses prevailing healthcare challenges but also actively participates in the global push toward minimally invasive procedures, thereby appealing to a growing segment of health-conscious patients and cost-sensitive healthcare systems. For investors, Olympus Corp. presents an intriguing opportunity characterized by resilient financial performance and strategic growth initiatives. The company has consistently demonstrated robust revenue generation, bolstered by its leadership in the endoscopy market, which accounts for a substantial portion of its sales. Furthermore, Olympus is strategically focused on expanding its product offerings through acquisitions and collaborations, reinforcing its commitment to innovation. The growing demand for minimally invasive surgeries, driven by advances in technology and patient preferences, positions Olympus favorably for future growth. With its solid foundation, continuous evolution, and commitment to sustainability, Olympus Corp. stands as a compelling investment option for those looking to align with a company dedicated to transforming healthcare and enhancing lives.

Intrinsic Value
2 702.13 JPY
Undervaluation 9%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
1.7%
=
Net Income
16.6B
/
Revenue
963.3B
What is the Net Margin of Olympus Corp?

Based on Olympus Corp's most recent financial statements, the company has Net Margin of 1.7%.